Kolon Ramps Up For Novel Osteoarthritis Cell Therapy
This article was originally published in PharmAsia News
South Korea's Kolon Life Science is gearing up for mass production of Invossa, the world's first cell-mediated gene therapy for osteoarthritis, as it prepares to file for a domestic approval and a US Phase III study. The venture also plans to raise around $114m to hike its biologics production capacity.
Register for our free email digests: